20.38
+2.07(+11.31%)
Currency In USD
| Previous Close | 18.31 |
| Open | 18.94 |
| Day High | 21.36 |
| Day Low | 18.76 |
| 52-Week High | 26.99 |
| 52-Week Low | 12.62 |
| Volume | 7,140 |
| Average Volume | 4,382 |
| Market Cap | 49.1M |
| PE | -6.42 |
| EPS | -2.92 |
| Moving Average 50 Days | 15.9 |
| Moving Average 200 Days | 16.82 |
| Change | 0.45 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $55.26 as of September 09, 2025 at a share price of $20.38. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $281.49 as of September 09, 2025 at a share price of $20.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 8:57 PM GMT
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin bein
vTv Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin bein
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 tria